KDM5D and prostate carcinoma: KDM5D can directly regulate the transcriptional activity of androgen, thereby affecting the sensitivity of CRPC to docetaxel.321 Additionally, silencing KDM5D could elevate MYBL2, thereby inducing docetaxel resistance in prostate cancer cells.322 As reported, miR-4661-5p is the upstream regulator of KDM5D.